Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 2
1992 3
1993 6
1994 31
1995 53
1996 62
1997 69
1998 68
1999 51
2000 68
2001 81
2002 51
2003 72
2004 72
2005 96
2006 111
2007 84
2008 87
2009 95
2010 100
2011 95
2012 126
2013 114
2014 127
2015 122
2016 118
2017 121
2018 93
2019 95
2020 97
2021 116
2022 107
2023 120
2024 150
2025 140
2026 59

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,793 results

Results by year

Filters applied: . Clear all
Page 1
Targeting RET mutation in medullary thyroid cancer.
Assi T, Tikriti Z, Shayya A, Ibrahim R. Assi T, et al. Pharmacogenomics. 2024 Feb;25(3):113-115. doi: 10.2217/pgs-2023-0234. Epub 2024 Mar 7. Pharmacogenomics. 2024. PMID: 38450459 No abstract available.
Update on Fundamental Mechanisms of Thyroid Cancer.
Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Prete A, et al. Front Endocrinol (Lausanne). 2020 Mar 13;11:102. doi: 10.3389/fendo.2020.00102. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32231639 Free PMC article. Review.
The incidence of thyroid cancer (TC) has increased worldwide over the past four decades. TC is divided into three main histological types: differentiated (papillary and follicular TC), undifferentiated (poorly differentiated and anaplastic TC), and medullary TC, ari …
The incidence of thyroid cancer (TC) has increased worldwide over the past four decades. TC is divided into three main histolo …
Medullary thyroid cancer with RET V804M mutation: more indolent than expected?
Frisco NA, Gunn AH, Thomas SM, Stang MT, Scheri RP, Kazaure HS. Frisco NA, et al. Surgery. 2023 Jan;173(1):260-267. doi: 10.1016/j.surg.2022.05.005. Epub 2022 Sep 21. Surgery. 2023. PMID: 36150924
Pathology was benign (27.9%), papillary thyroid cancer alone (1.5%), C-cell hyperplasia (23.5%), and medullary thyroid cancer (47.1%; median tumor size = 3.0 mm). ...In adjusted modeling, a preoperative calcitonin >5 pg/mL was associated with having …
Pathology was benign (27.9%), papillary thyroid cancer alone (1.5%), C-cell hyperplasia (23.5%), and medullary thyroid …
Targeting RET in medullary thyroid cancer.
Newbold K, Cheng L. Newbold K, et al. Endocr Relat Cancer. 2025 Aug 20;32(8):e240291. doi: 10.1530/ERC-24-0291. Print 2025 Aug 1. Endocr Relat Cancer. 2025. PMID: 40742350 Review.
ABSTRACT: Medullary thyroid cancer (MTC) is a rare cancer, accounting for 2-3% of all thyroid cancers. Point mutations in the RET proto-oncogene can be detected in 25-65% of MTC. These mutations commonly occur in the cysteine-rich …
ABSTRACT: Medullary thyroid cancer (MTC) is a rare cancer, accounting for 2-3% of all thyroid cancers. Point …
Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.
Zhang W, Lin S, Wang Z, Zhang W, Xing M. Zhang W, et al. J Clin Endocrinol Metab. 2024 Nov 18;109(12):3166-3175. doi: 10.1210/clinem/dgae327. J Clin Endocrinol Metab. 2024. PMID: 38735658 Free PMC article.
CONTEXT: The role of RET/PTC rearrangement in the clinical outcomes of papillary thyroid cancer (PTC) is controversial and remains to be clearly undefined. ...Similar results were observed with BRAF/RAS and TERT promoter mutations. Mechanistically, …
CONTEXT: The role of RET/PTC rearrangement in the clinical outcomes of papillary thyroid cancer (PTC) is controversial …
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.
Ryška A, Capdevila J, Dettmer MS, Elisei R, Führer D, Hadoux J, Jarząb B, Locati LD, Newbold K, Tallini G, Uccella S, Wirth L, Singh R, Simon IM, Camacho P, Fugazzola L. Ryška A, et al. Eur Thyroid J. 2025 Jul 7;14(4):e250024. doi: 10.1530/ETJ-25-0024. Print 2025 Aug 1. Eur Thyroid J. 2025. PMID: 40540622 Free PMC article. Review.
As new precision oncology therapies become available in the thyroid cancer (TC) treatment landscape, appropriate and timely biomarker testing is crucial for treatment selection and requires a multidisciplinary approach. ...As anaplastic TC is a highly aggressive dis …
As new precision oncology therapies become available in the thyroid cancer (TC) treatment landscape, appropriate and timely bi …
RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer.
Prabhash K, Saldanha E, Patil V, Bal M, Reddy P S, Sanjeev A, Kumar R, Poojary D, Noronha V, Menon N, Mittal N, Trivedi V, Nambiar K, Mishra R, Tanwar N, Malhotra R, Pange P, Gupta V, Veldore VH, Chougule A, Chaturvedi P, Dutt A, Chandrani P. Prabhash K, et al. JCO Precis Oncol. 2024 May;8:e2300622. doi: 10.1200/PO.23.00622. JCO Precis Oncol. 2024. PMID: 38754058
PURPOSE: Medullary thyroid cancer (MTC) is a rare cancer originating from parafollicular C cells of the thyroid gland. ...We performed clinically relevant variant analysis, molecular pathway analysis, tumor immune-microenvironment analysis, and structu …
PURPOSE: Medullary thyroid cancer (MTC) is a rare cancer originating from parafollicular C cells of the thyroid …
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R, Romei C. Elisei R, et al. Endocrine. 2023 Aug;81(2):206-215. doi: 10.1007/s12020-023-03368-w. Epub 2023 May 17. Endocrine. 2023. PMID: 37195581 Review.
According to their cell origin and histological features, different histotypes of thyroid carcinoma are described. Genetic alterations involved in the pathogenesis of thyroid cancer have been described and it has been shown that alterations of the RET …
According to their cell origin and histological features, different histotypes of thyroid carcinoma are described. Genetic alteration …
Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.
Greenberg LA. Greenberg LA. Prim Care. 2024 Sep;51(3):483-494. doi: 10.1016/j.pop.2024.03.006. Epub 2024 May 23. Prim Care. 2024. PMID: 39067973 Review.
Multiple endocrine neoplasia type 2A (MEN2A) and Multiple endocrine neoplasia type 2B (MEN2B) are autosomal dominant genetic syndromes because of a germline variant in the 'rearranged during transfection' (RET) proto-oncogene. There are common RET mutations c …
Multiple endocrine neoplasia type 2A (MEN2A) and Multiple endocrine neoplasia type 2B (MEN2B) are autosomal dominant genetic syndromes becau …
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D, Santoro M, Schlumberger M. Salvatore D, et al. Nat Rev Endocrinol. 2021 May;17(5):296-306. doi: 10.1038/s41574-021-00470-9. Epub 2021 Feb 18. Nat Rev Endocrinol. 2021. PMID: 33603219 Review.
Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein have been found in diverse thyroid cancer subtypes. RET gene rearrangements are observed in papillary thyroid carcinoma, which result in RET fusi …
Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein have been found in diverse thyroid …
2,793 results